ArticleThe ocular surface2020
Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis.
Article in The ocular surface, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Ocular involvement in toxic epidermal necrolysis syndrome at Chelsea and Westminster Hospital: a 10-year retrospective analysis and review of current literature.Eye (London, England) · 2026Review
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Ophthalmic Management and Treatment.Vision (Basel, Switzerland) · 2025Review
- Mycoplasma-Induced Rash and Mucositis: Ocular Manifestations, Treatment and Outcomes in a Paediatric Population.Journal of paediatrics and child health · 2025Article
- Conjunctival squamous metaplasia on amniotic membrane in Stevens-Johnson syndrome: a case report.BMC ophthalmology · 2024Article
- Amnion as an Innovative Antiseptic Carrier: A Comparison of the Efficacy of Allogeneic and Xenogeneic Transplantations in the Context of Burn Therapy.Medicina (Kaunas, Lithuania) · 2024Article
- Clinical Characteristics and Treatment of Ophthalmic Sequelae of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at a Tertiary Eyecare Centre in Hungary.Ophthalmology and therapy · 2024Article
- Amniotic membrane transplantation: structural and biological properties, tissue preparation, application and clinical indications.Eye (London, England) · 2024Review
- Idiopathic toxic epidermal necrolysis in a pediatric patient.Proceedings (Baylor University. Medical Center) · 2024Article
- Self-Retained, Sutureless Amniotic Membrane Transplantation for the Management of Ocular Surface Diseases.Journal of clinical medicine · 2023Article
- Ophthalmic Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review.Ophthalmology and therapy · 2023Review
- Novel technique for amniotic membrane transplantation for acute Stevens-Johnson syndrome/toxic epidermal necrolysis patients.Heliyon · 2023Article
- The developments in amniotic membrane transplantation in glaucoma and vitreoretinal procedures.International ophthalmology · 2023Review
- Updates in SJS/TEN: collaboration, innovation, and community.Frontiers in medicine · 2023Review
- Personalized 3D-printed amniotic fornical ring for ocular surface reconstruction.International journal of bioprinting · 2023Article
- Cytokeratin profile and keratinocyte gene expression in keratinized lid margins of patients with chronic Stevens-Johnson syndrome.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Stevens-Johnson Syndrome Following Non-steroidal Anti-inflammatory Drugs: A Real-World Analysis of Post-marketing Surveillance Data.Frontiers in pediatrics · 2022Article
- Visual function and quality of life in patients with Stevens-Johnson syndrome who received acute protocol-based ocular care.Frontiers in toxicology · 2022Article
- Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review.International journal of women's dermatology · 2021Review
- Article
- [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
purposeTo report the long-term outcomes of amniotic membrane (AM) use in the form of transplantation (AMT) and self-retained amniotic membrane (ProKera® device, PD) in acute Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).
methodsElectronic records of all patients with a diagnosis of SJS/TEN at Massachusetts Eye and Ear between January 2008 and January 2018 were reviewed. Patients who received AM in acute SJS/TEN were selected. Only patients with follow-up ≥ 3 months after discharge were included.
resultsData of 55 eyes of 29 patients were analyzed. All 55 eyes received the first AM at a median interval of 5 days (inter-quartile range (IQR): 3-7 days) after onset of skin rash. Fifty-six percent of eyes (31/55) received AMT while 44% (24/55) received PD. Forty percent of eyes (22/55) required a repeat AMT or PD. Median follow-up after initial AM was 2.5 years (IQR: 1.2-3.6 years). At last follow-up, the best-corrected visual acuity was ≥20/40 in 87% of eyes (48/55). The most common complications in the chronic phase were meibomian gland disease and dry eye, seen in 78% of eyes (43/55) and 58% of eyes (32/55) respectively.
conclusionsLong-term results show that early use of AM in the acute phase of SJS/TEN may be effective in mitigating severe vision loss after SJS/TEN. However, eyelid-related complications and dry eye remain a common problem even with the use of AM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.